Great Point Partners LLC Position in Ptc Therapeutics INC (PTCT) Upped as Share Price Declined

March 14, 2018 - By Darrin Black

Investors sentiment increased to 1.71 in 2017 Q3. Its up 0.79, from 0.92 in 2017Q2. It is positive, as 13 investors sold PTCT shares while 28 reduced holdings. 25 funds opened positions while 45 raised stakes. 32.89 million shares or 5.85% more from 31.07 million shares in 2017Q2 were reported. Cubist Systematic Strategies Ltd Liability Company stated it has 4,662 shares. 64,160 are held by California State Teachers Retirement System. Moreover, Point72 Asset Management LP has 0.04% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 400,000 shares. New York-based Pinnacle Associate Ltd has invested 0.12% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Moreover, Balyasny Asset Ltd Limited Liability Company has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). 11,582 are owned by Employees Retirement Sys Of Ohio. Numeric Invsts Ltd Com invested in 470,982 shares or 0.07% of the stock. Secor Lp holds 0.05% or 23,722 shares in its portfolio. Moreover, Bogle Mngmt LP De has 0.76% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT). Parametric Associates Lc has 26,739 shares. Sectoral Asset Inc accumulated 170,535 shares. Vanguard Group has 2.94 million shares for 0% of their portfolio. Wells Fargo Mn has invested 0% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Prudential Financial Inc holds 0% or 51,227 shares. Aqr Capital Limited Liability Company accumulated 0% or 73,614 shares.

Since January 3, 2018, it had 0 insider purchases, and 4 sales for $61,523 activity. Utter Christine Marie also sold $7,280 worth of PTC Therapeutics, Inc. (NASDAQ:PTCT) shares. Shares for $12,675 were sold by Almstead Neil Gregory on Friday, January 5.

Jeffrey Jay increased its stake in Ptc Therapeutics Inc (PTCT) by 323.08% based on its latest 2017Q3 regulatory filing with the SEC. Great Point Partners Llc bought 840,000 shares as the company’s stock declined 3.95% while stock markets rallied. The hedge fund run by Jeffrey Jay held 1.10 million shares of the health care company at the end of 2017Q3, valued at $22.01 million, up from 260,000 at the end of the previous reported quarter. Great Point Partners Llc who had been investing in Ptc Therapeutics Inc for a number of months, seems to be bullish on the $1.27B market cap company. The stock increased 1.67% or $0.5 during the last trading session, reaching $30.39. About 1.03 million shares traded or 10.34% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has risen 104.51% since March 14, 2017 and is uptrending. It has outperformed by 87.81% the S&P500.

Great Point Partners Llc, which manages about $935.83 million and $514.03M US Long portfolio, decreased its stake in Ignyta Inc (NASDAQ:RXDX) by 507,571 shares to 1.24M shares, valued at $15.34 million in 2017Q3, according to the filing. It also reduced its holding in Arena Pharmaceuticals Inc by 1.08M shares in the quarter, leaving it with 1.36 million shares, and cut its stake in Zogenix Inc (Put).

More important recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: which released: “PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the …” on February 20, 2018, also published article titled: “Earnings Reaction History: PTC Therapeutics, Inc., 40.0% Follow-Through …”, published: “PTC Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results …” on March 06, 2018. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) was released by: and their article: “PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for …” with publication date: February 13, 2018.

PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage

Among 12 analysts covering PTC Therapeutics (NASDAQ:PTCT), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. PTC Therapeutics had 38 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Sector Perform” rating given on Friday, November 11 by RBC Capital Markets. The rating was upgraded by Credit Suisse to “Outperform” on Monday, November 14. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Buy” rating given on Thursday, February 22 by Citigroup. RBC Capital Markets maintained it with “Hold” rating and $1500 target in Wednesday, August 9 report. The firm has “Outperform” rating by RBC Capital Markets given on Friday, July 31. The firm has “Hold” rating by Cowen & Co given on Friday, June 30. RBC Capital Markets maintained the stock with “Hold” rating in Wednesday, March 7 report. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) has “Neutral” rating given on Wednesday, February 24 by Citigroup. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Hold” rating by RBC Capital Markets on Thursday, September 14. The rating was upgraded by Citigroup on Friday, November 11 to “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: